A recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and that the process pharmaceutical companies use to determine price is too opaque.
A recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and that the process pharmaceutical companies use to determine price is too opaque.
Joint Clinical Assessment (JCA) provides a common EU-level clinical assessment, but national HTA and...
Read moreManufacturers should not wait for final HTA scopes to test whether their evidence package can addres...
Read moreBe the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​
Get in touch